Literature DB >> 23912496

Mosaicism for GJB1 mutation causes milder Charcot-Marie-Tooth X1 phenotype in a heterozygous man than in a manifesting heterozygous woman.

I Borgulová1, R Mazanec, I Sakmaryová, M Havlová, D Safka Brožková, P Seeman.   

Abstract

Charcot-Marie-Tooth (CMT) disease is a heterogeneous disorder of the peripheral nervous system that collectively affects approximately 1 in 2,500 individuals, thus making it the most common inherited neurologic disorder. X-linked inheritance may account for 10-20 % of CMT neuropathy. We report a Czech family with a 30-year-old woman affected by CMT since the age of 10 years, originally as an isolated case. Nerve conduction study (NCS) showed demyelinating neuropathy, and DNA testing revealed a novel heterozygous gap junction beta-1 protein (GJB1) mutation c.784_786delTA. The same mutation, but surprisingly in heterozygous state, was subsequently found in her subjectively healthy father and later also in one of her sisters but not in her two other sisters. NCS showed intermediate type of motor and sensory neuropathy in these two females manifesting heterozygotes and normal results in the other healthy sisters and one brother, all without the c.784_786delTA mutation. The father has a phenotype milder than his daughter and has only subclinical signs of CMT. The index female patient had normal karyotype 46, XX, and normal FISH for centromeric X chromosome. We concluded that the proband's father is a heterozygote due to the somatic mosaicism for the GJB1 mutation in his leukocytes (detected by DNA sequencing) and also in his germ cells as confirmed by the unexpectedly different genotypes in his four daughters. Quantitative analysis revealed a mutated signal in 25:75 allele proportion of mutated to healthy allele in the mosaic father. This study has important consequences for genetic counseling and prognosis in CMTX1 families.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912496     DOI: 10.1007/s10048-013-0368-7

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  15 in total

1.  Somatic mosaicism in Charcot-Marie-Tooth type X disease.

Authors:  A Kochanski; A Nowakowski; M Kawulak; D Kabzińska; I Hausmanowa-Petrusewicz
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

2.  Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP): reliable detection of the CMT1A duplication and HNPP deletion using 8 microsatellite markers in 2 multiplex PCRs.

Authors:  P Seeman; R Mazanec; J Zidar; S Hrusáková; M Ctvrtecková; B Rautenstrauss
Journal:  Int J Mol Med       Date:  2000-10       Impact factor: 4.101

3.  Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease.

Authors:  A F Hahn; C F Bolton; C M White; W F Brown; S E Tuuha; C C Tan; P J Ainsworth
Journal:  Ann N Y Acad Sci       Date:  1999-09-14       Impact factor: 5.691

4.  Connexin32-null mice develop demyelinating peripheral neuropathy.

Authors:  S S Scherer; Y T Xu; E Nelles; K Fischbeck; K Willecke; L J Bone
Journal:  Glia       Date:  1998-09       Impact factor: 7.452

Review 5.  Connexin32 and X-linked Charcot-Marie-Tooth disease.

Authors:  L J Bone; S M Deschênes; R J Balice-Gordon; K H Fischbeck; S S Scherer
Journal:  Neurobiol Dis       Date:  1997       Impact factor: 5.996

6.  Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families.

Authors:  G Nicholson; J Nash
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

7.  Novel 95G>A (R32K) somatic mosaic connexin 32 mutation.

Authors:  Steven K Baker; Cara C Reith; Peter J Ainsworth
Journal:  Muscle Nerve       Date:  2008-11       Impact factor: 3.217

8.  Gap junction beta 1 (GJB1) gene mutations in Italian patients with X-linked Charcot-Marie-Tooth disease.

Authors:  Paola Mandich; Marina Grandis; Alessandro Geroldi; Massimo Acquaviva; Alessandra Varese; Rossella Gulli; Paola Ciotti; Emilia Bellone
Journal:  J Hum Genet       Date:  2008-04-01       Impact factor: 3.172

Review 9.  Mechanisms and consequences of somatic mosaicism in humans.

Authors:  Hagop Youssoufian; Reed E Pyeritz
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

10.  Six new gap junction beta 1 gene mutations and their phenotypic expression in Czech patients with Charcot-Marie-Tooth disease.

Authors:  Dana Brozková; Radim Mazanec; Jana Haberlová; Iva Sakmaryová; Ivan Subrt; Pavel Seeman
Journal:  Genet Test Mol Biomarkers       Date:  2010-02
View more
  5 in total

Review 1.  Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Authors:  José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

2.  Genome-wide uniparental diploidy of all paternal chromosomes in an 11-year-old girl with deafness and without malignancy.

Authors:  Irena Borgulová; Inna Soldatova; Martina Putzová; Marcela Malíková; Jana Neupauerová; Simona Poisson Marková; Marie Trková; Pavel Seeman
Journal:  J Hum Genet       Date:  2018-04-10       Impact factor: 3.172

Review 3.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

4.  A novel TAZ gene mutation and mosaicism in a Polish family with Barth syndrome.

Authors:  Barbara Zapała; Teresa Płatek; Iwona Wybrańska
Journal:  Ann Hum Genet       Date:  2015-03-16       Impact factor: 1.670

5.  Mosaicism for a pathogenic MFN2 mutation causes minimal clinical features of CMT2A in the parent of a severely affected child.

Authors:  Katherine Schon; Olivera Spasic-Boskovic; Kim Brugger; Tracey D Graves; Stephen Abbs; Soo-Mi Park; Gautam Ambegaonkar; Ruth Armstrong
Journal:  Neurogenetics       Date:  2017-01-06       Impact factor: 2.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.